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UNIT A21.1MRI of Breast Lesions
Magnetic Resonance Mammography (MRM) has evolved in the last 17 years as a
powerful tool for diagnosing breast lesions. The tomographic aspect of imaging and a
high soft tissue contrast without radiation proved to have the highest sensitivity in
detecting especially small invasive breast lesions. Some major advantages of MRM are
the detection of multifocality/multicentricity; differentiation between scar and tumor;
delineation of breast implants; analysis of “surprising” lesions in the contralateral breast;
search for primary tumor in a CUP syndrome (Cancer of Unknown Primary) after having
detected malignant lymph nodes in the axillary region; and early analysis of response to
chemotherapy. Several unanswered questions remain, including: the varying specificities
reported in the literature, depending on the technical and methodological variations and
problems; MRM’s high price; the lack of detection of microcalcification and some cases
of DCIS (Ductal Carcinoma in situ); the need for contrast and sophisticated data
evaluation as well as delineation of hormonal aspects; and a broad variety of technical
pitfalls.
For differentiating between malignant and benign lesions, a high spatial as well as
temporal resolution is of utmost importance. Therefore, a so-called dynamic technique
(i.e., the repetitive imaging of the same slices before and in short time intervals after the
injection of contrast medium), is essential to detect the differences in initial enhancements
between malignant and benign lesions which are reflected by the tumorangiogenetic
vascular network of malignant lesions. This network results not only in an increased
number of vessels, but also and especially in a changed vascular architecture consisting
of primitive membranes, including defects in basal membranes, which are responsible for
an increased interstitial space and AV-shunts, which might explain the so-called wash-out
effect, i.e., the decrease of signal intensity after the initial rise in the first 1 to 2 min after
contrast agent injection. The protocols given here focus on dynamic techniques at high
field strength (1.5 T), where the majority of experience has occurred in MR Mammogra-
phy in the last decade.
BASIC
PROTOCOL
DYNAMIC MR MAMMOGRAPHY
Magnetic Resonance Mammography was mainly evaluated at field strengths of 1.0 T and
1.5 T. There is only little experience at mid-field (0.5 T) or low field (0.2 T and lower).
At low field strength some compromises have to be made, for example, increase of
contrast medium, decrease of repeat time, and increase of flip angle in order to compensate
the relatively low decrease of T1 relaxation time induced by gadolinium based contrast
agents compared with high fields. The sequences described herein are based on the
author’s experience with a Philips 1.5 T ACS II and a Siemens 1.5 T Vision Scanner, but
are expected to be equally applicable to devices from other manufacturers.
The following technical advice is given to the technologist and radiologist, who, espe-
cially in the field of dynamic MR Mammography, have to work together as an effectively
coordinated team in order to make the examination successful.
Dynamic MR Mammography can be performed either as a multi-slice 2-D or a dynamic
3-D sequence. The 3-D sequence offers higher through-plane resolution than the 2-D
sequence; however, some machines and coils still lack sufficient signal homogeneity in
3-D techniques. In these cases, the critical subtraction images can be deteriorated by
artifacts. Most machines can perform multi-slice 2-D gradient echo sequences in a
sufficient homogeneity over a wider range of field of view, which is especially important
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in imaging of both breasts in transverse or coronal orientation and for a later analysis of
lesions in subtracted images.
Table A21.1.1 lists the hardware necessary to perform the procedure along with the major
appropriate parameters. The double breast coil is essential in order to evaluate both breasts
simultaneously. This is especially important to compare enhancement of both breasts, i.e.,
in cases of in-flow phenomena, DCIS, inhomogeneities, and detection of lesions in either
one or both breasts simultaneously. Once the contrast medium is injected, the simultane-
ous examination of both breasts is strongly recommended.
Patients having any ferromagnetic metal should be excluded from the examination, e.g.,
ferromagnetic particles, pacemakers, etc. This should be clarified by phone, before the
MR examination is scheduled.
The currently available MR breast coils and MR machines have relatively limited space
because of the space taken up by the doublebreast coil. In our experience, patients
weighing more than 95 kg cannot be put in today’s machines, and so patients should be
screened by phone in advance. Patients taking hormones (i.e., hormone replacement
therapy after menopause) should be advised to stop taking the hormones for ∼3 months
before MRM examination. Patients in the menstrual cycle can normally be examined.
However, the progesterone effect in the second half of the menstrual cycle usually induces
a slightly increased contrast uptake, which might be a problem for inexperienced readers.
Therefore, an MR examination in the first half of the menstrual cycle, at least between
day 7 and 20, is advisable but not necessary.
Besides pacemakers or ferromagnetic parts, other exclusion criteria are: previous allergies
to gadolinium (Gd); unclear implants; clip implantations (especially in arteries or in the
breast); psychiatric conditions, or claustrophobia. If there is any doubt about the possi-
bility of some unclear implants, please contact the website http://www.mrisafety.com, for
further information.
Since many technical and methodological pitfalls can occur, it is strongly advised to
perform an MRM examination only if sufficient experience in analyzing the images is
available.
Table A21.1.1 Equipment Parameters for Dynamic MR Mammography
Coil type Bilateral circularly polarized breast coil (or
phased array double breast coil, if available)
Gradient coil strength 15-25 mT/m (or whatever the system permits)
Cardiac gating No
Peripheral gating No
Respiratory gating No
Oxygen Usually not
Motion cushions Very useful
Subtraction software Very useful
Automatic tuning Yes, but no additional tuning after the first
pre-contrast scan (“switched off” or “offline”
technique)
Fast dynamic technique Yes
Automatic image subtraction Yes
Signal intensity versus time
curves
Very useful
Use of contrast agent Yes
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There are two major disadvantages of low field strength. These are, first, the reduced
signal-to-noise, and, second, a smaller decrease in T1 induced by gadolinium based
contrast agents as a result of the initially low T1 values of the tissue (for example, 600
msec at 0.5 T, 900 msec at 1.5 T). However, these disadvantages can be compensated at
mid field by additional use of strong gradients (≥15 mT/m) and high slew rates (≥15 to
25 T/m/sec). We also recommend increasing sensitivity towards Gd at low field by making
the sequence more T1 dependent (shortening of repeat time, increase of contrast medium
dose, etc.).
Besides the exclusion criteria listed above, we advise that one rigorously select for strong
indications for MR Mammography. Today, one should perform this relatively expensive
and time-consuming technique only if high-quality X-ray mammography and ultrasound
examinations still leave some doubts about the presence or absence, the malignancy or
benignancy of a lesion, and/or the multicentricity or multifocality of lesions.
Sequence overview in dynamic MRM (1.5 T)
Table A21.1.2 gives an overview of the sequences used in the complete dynamic MR
examination at 1.5 T (for example, a Philips 1.5 T ACS II machine). After a short scout
sequence, a coronal T1-weighted gradient-echo and a transverse T2-weighted turbo-spin-
echo sequence follow. The key part of this dynamic procedure is a T1-weighted gradient-
echo sequence before and 7 times after injection of contrast agent. Finally, the T1-weighted
coronal sequence is repeated so that a complete pre- and post-contrast image data set is
available in two orientations. In special patients (see Critical Parameters and Trou-
bleshooting) a dynamic examination in coronal orientation is advised; in these cases the
orientations of the sequences outlined in Table A21.1.2 are listed in parentheses.
Materials
Normal saline (0.9% NaCl), sterile
Extravascular contrast agent (e.g., Magnevist, Omniscan, or Prohance)
NOTE: Be sure that technicians and nurses have immediate access to any emergency
equipment that may be relevant to a given study, or that may be needed for a particular
patient, such as crash carts or oxygen.
Set up equipment and patient
1. Interview (screen) the patient to ensure that she has no contraindications such as
cardiac pacemakers or other implants containing ferromagnetic materials. Also,
determine if the patient has any health conditions that may require the presence of
Table A21.1.2 Dynamic MRM Examination at 1.5 Ta
Sequence Time
1. Scout (transverse + coronal) 37 sec
2. Coronal (transverse) T1-weighted gradient echo 1 min, 47 sec
3. Transverse (coronal) T2-weighted turbo spin echo 3 min, 12 sec
4. Transverse (coronal) T1-weighted gradient echo 1 min, 0 sec
Injection of contrast agent: 0.1 mmol/kg Gd-DTPA intravenous (or 0.2 ml/kg per dose)
5. Transverse (coronal) T1-weighted gradient echo
(7 repetitions)
1 min, 0 sec per scan (total 7
min)
Automatic image subtraction (between sequences 5 and 4)
6. Coronal (transverse) T1-weighted gradient echo 1 min, 47 sec
aTotal scanning time of these sequences is 15 min and 23 sec.
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special emergency equipment during the scanning procedure, or if she will need
sedation medication necessitating the use of appropriate monitoring equipment. Use
sedation only if it cannot at all be avoided. If you are unsure about the presence of
any ferromagnetic materials, please contact the referring physician or the web site
http://www.mrisafety.com.
The presence of any ferromagnetic metals may be a health hazard to the patient when she
is inside the magnet, and will also affect the imaging. If in doubt as to the exact composition
of the items, it is best to exclude patients with any metal implants; see also Shellock (1996)
for discussion of what implants may be safely scanned using magnetic resonance.
Patients may be accompanied into the magnet room by a friend or family member, who can
sit in the room during the scan and comfort the patient as needed. This companion must
be screened as well to ensure the absence of loose metal objects on the body or clothing.
It is strongly advised that this accompanying person does not talk to the patient during the
examination to avoid any movements.
2. Clarify that the patient has had no previous allergy to or contraindications against
Gd. Explain the examination in detail and have the patient sign any necessary consent
form.
3. Have the patient remove all jewelry and change into a gown to eliminate any metal
that might be found in clothing.
4. Have the patient wash off any mascara and other makeup to avoid local tissue heating
and image artifacts. Especially look for metallic rings in any body parts.
5. Inform the patient about what will occur during the procedure, what she will
experience while in the magnet, and how to behave, including the following:
a. If earphones or headphones are used to protect the ears from the loud sounds
produced by the gradients, the patient will be asked to wear these, but will be able
to communicate with you at any time during the imaging.
b. The patient will be given a safety squeeze-bulb or similar equipment to request
assistance at any time (demonstrate how this works).
c. Explain to the patient that movement of the head or coughing deteriorates image
quality. For good results the patient should not talk, and should avoid or minimize
swallowing or other movement during each scan—i.e., as long as the banging
sounds continue. Between scans, talking and swallowing are allowed in most
cases, but should be avoided when comparative positional studies are being
performed; the patient will be informed when this is the case.
d. Nevertheless, the patient may call out any time if she feels it necessary.
6. Help the patient mount onto the table and stand beside the patient during positioning
in the magnet. Either before or right after the patient lies down, set up any triggering
devices or other monitoring equipment that is to be used.
7. If the patient is nervous, calm her and talk to her as much as possible before
positioning her into the machine. After having positioned her, explain that you will
not talk to her in order to avoid any motion, unless communication is necessary.
8. Insert the plastic cannula into the cubital vein, fix it and connect a plastic tube before
putting the patient into the machine. After positioning the patient in the machine,
connect the plastic tube with the automatic injector filled with a sufficient dose of
contrast medium and a bolus of sodium chloride (physiological concentration).
9. Place patient’s breasts in the coil.
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Be sure that each breast is not deformed within the coil, since a later description of the
exact position of a lesion in the breast is performed by describing the breast as a
half-spherical mass with a nipple at the top and the lesion being positioned as xyz mm
medially, laterally, cranially, caudally or dorsally in relation to the nipple.
10. Be sure that the patient has stretched arms along the body and not bent arms crossed
over the head, in order to guarantee constant influx of the contrast medium.
Injection of contrast medium is performed in the magnet without moving the patient out of
the magnet.
11. If needed, place a pillow or other support under the knees to make the examination
more comfortable for the patient. Have the patient cushioned as comfortably as
possible in order to let her relax and to obtain images without motion artifacts.
12. Use the centering light to position the middle of the breast coil (this should coincide
with the middle of the breast at the level of the nipple) and to put her into the isocenter
of the magnet.
13. If the patient is very nervous, try to calm her or bring her out of the magnet after a
few seconds and talk to her. In most cases this is sufficient.
Try to avoid any medical sedation, as that reduces the possibility of exchanging information
or of detecting an allergy, and it may induce a paradoxic reaction.
Sequence 1: Rapid two-plane positioning pilot
14. To validate the patient’s position, run the system’s pilot (or scout) scan to ensure
correct location of the breast in two dimensions, using the imaging sequence given
in Table A21.1.3 or similar parameters. This sequence usually consists of two
orthogonal planes to allow localization.
Sequence 2: T1-weighted gradient echo
15. Run sequence 2 according to Table A21.1.4.
This coronal T1-weighted sequence allows the complete examination of the axillary region.
The slice thickness in this and all following sequences depends on breast size and varies
Table A21.1.3 Primary Clinical Imaging Parameters for Pilot Scan (Sequence 1)
Patient position Prone
Scan type Spin echo (multi-slice,
half-Fourier)
Imaging plane (orientation) Transverse and coronal
Central slice or volume center Middle of the breast (usually at
the nipple)
Echo time (TE) 13 msec
Repeat time (TR) 121 msec
Flip angle (FA) 90°
Fields of view (FOVx, FOVy) 450 mm, 450 mm
Resolution (∆x, ∆y) 2.53 mm, 1.76 mm
Number of data points collected (Nx, Ny) 178, 256
Slice thickness (∆z) 5 mm
Number of slices 5 in each orientation
Slice gap 3 mm
Number of acquisitions (Nacq) 1
Scan time 37 sec
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between 3 and 5 mm; correspondingly, the gap between the slices varies between 0.1 and
1.0 mm, depending on breast size. Slice thickness and slice gaps are kept constant
throughout the whole examination of the patient.
Sequence 3: T2-weighted turbo spin echo (TSE)
16. Run sequence 3 according to Table A21.1.5.
The additional evaluation of signal intensity in T2-weighted images is important for the
delineation of fluid cysts, myxoid fibroadenomas, edema, blood, abscesses, septations in
the lesion, etc.
Table A21.1.4 Primary Clinical Imaging Parameters for T1-Weighted Gradient
Echo (Sequences 2 and 6)
Patient position Prone
Scan type T1-weighted 2-D gradient echo
Imaging plane (orientation) Coronal
Central slice or volume center Middle of the breast
Echo time (TE) 5 msec
Repeat time (TR)a 100 msec
Flip angle (FA) 80°
Fields of view (FOVx, FOVy) 350 mm, 315 mm
Resolution (∆x, ∆y) 1.37 mm, 1.53 mm
Number of data points collected (Nx, Ny) 256, 206
Slice thickness (∆z) 3–5 mm (depending on breast size)
Number of slicesb 24
Slice gap 0.1–1.0 mm (depending on breast
size)
Number of acquisitions (Nacq) 2
Scan time 1 min, 47 sec
aTR is 100 msec for the Philips ACSII-1.5 T-machine or 240 msec for the Siemens Vision 1.5T machine.
b3 slabs of 8 slices each for the Phillips machine or 1 slab of 24 slices for the Siemens machine.
Table A21.1.5 Primary Clinical Imaging Parameters for T2-Weighted Turbo
Spin Echo (TSE; Sequence 3)
Patient position Prone
Scan type T2-weighted turbo spin echo
Imaging plane (orientation) Transverse
Central slice or volume center Middle of the breast
Echo time (TE) 300 msec
Echo train length (ETL) 35
Repeat time (TR) 4000 msec
Flip angle (FA) 90°
Fields of view (FOVx, FOVy) 315 mm, 350 mm
Resolution (∆x, ∆y) 1.64 mm, 1.37 mm
Number of data points collected (Nx, Ny) 192, 256
Slice thickness (∆z) 3–5 mm
Number of slices 24
Slice gap 0.1–1.0 mm
Number of acquisitions (Nacq) 1
Scan time 3 min, 12 sec
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Sequence 4: Transverse T1-weighted gradient echo (pre-constrast scan)
Since a variety of pitfalls can occur, this dynamic scan procedure has to be carefully
checked at three different checkpoints (see Fig. A21.1.1). Checkpoint I is just before the
precontrast scan. At this point, define the exact position of the breast in the coil by
analyzing the scout scan and correct any deformation or malpositioning of the nipple. The
orientation of the dynamic slices is checked (see below), the phase encoding direction is
optimized (see below), and the scan parameters are finally controlled.
17. Perform checkpoint I.
18. Run sequence 4 according to Table A21.1.6.
19. After running sequence 4, checkpoint II of the dynamic scan is reached. At this point,
i.e., after the precontrast scan and before the injection of contrast medium (see Fig.
A21.1.1), evaluate the homogeneity of the coil by observing how constant the fat
signal is across both breasts. This is to ensure that the placement of the coil is
checkpoints
dynamic MRM
contrast + NaCI
check I   check II waiting
time
check III
post 1 ..2 ..3 ..4 ..5 ..6 ..7
X X X
pre
Figure A21.1.1 Special sequential performance of the scans in the dynamic MRM (sequences 4
to 6). There are 3 “checkpoints” where the examiner has to control the performance: before the
pre-contrast scan (checkpoint I), after the pre-contrast scan (checkpoint II), and after the last
post-contrast scan (checkpoint III; see text).
Table A21.1.6 Primary Clinical Imaging Parameters for T1-Weighted Gradient
Echo (Pre-Contrast) Scan (Sequence 4)
Patient position Prone
Scan type T1-weighted 2-D gradient echo
Imaging plane (orientation) Transverse
Central slice or volume center Middle of the breast
Echo time (TE) 5 msec
Repeat time (TR)a 100 msec
Flip angle (FA) 80°
Fields of view (FOVx, FOVy) 315 mm, 350 mm
Resolution (∆x, ∆y) 1.23 mm, 1.37 mm
Number of data points collected (Nx, Ny) 256, 256
Slice thickness (∆z) 3–5 mm
Number of slicesb 24
Slice gap 0.1–1.0 mm
Number of acquisitions (Nacq) 1
Scan time 1 min, 0 sec
aTR is 100 msec for the Philips ACSII-1.5 T-machine or 240 msec for the Siemens Vision 1.5T machine.
b3 slabs of 8 slices each for the Phillips machine or 1 slab of 24 slices for the Siemens machine.
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appropriate and no tuning artifacts occurred and that the complete breast parenchyma
is included in the dynamic scans. Be sure that the automatic adjustment is switched
off for the following post-contrast scans in order to ensure an identical adjustment
position in pre- and post-contrast scans. Look for and analyze possible artifacts (e.g.,
metals, clips). If the patient had shown any motion, advise her not to move and in
that case, the pre-contrast scan is repeated once again.
Sequence 5: Transverse T1-weighted gradient echo (post-contrast scan)
20. Leaving the patient in the magnet, inject a dose of 0.1 mmol/kg (= 0.2 ml/kg)
Gd-DTPA at a bolus of 3 ml/sec followed by a sodium chloride bolus (physiological
concentration) of 20 ml (if the position is in the cubital vein) or 30 ml (if the position
is at the lower arm or hand vein).
21. After the end of the sodium chloride injection, wait 20 sec before beginning the first
post-contrast scan, in order to let the contrast medium flow in and to be able to
compare the results with previously published dynamic procedures. This waiting time
also makes it possible to avoid artifacts from interleaved data acquisitions of different
slices during the post-contrast scans.
22. After that waiting time, repeat without interruption seven post-contrast acquisitions
with identical measurements and sequence parameters as the pre-contrast scan. The
total scan time is 7 min (Table A21.1.7).
Automatic image subtraction
23. The software will perform an automatic image subtraction as soon as data points have
been measured; this automatic image subtraction is finished shortly after the end of
sequence 5.
24. Data evaluation begins at the monitor as soon as images are displayed on the screen
(see Table A21.1.2). As soon as the dynamic scan is finished, an automatic subtraction
allows for a complete fat subtraction and a quick detection of enhancing lesions
among these “innumerable” images. The subtraction images also allow the detection
of possible motions or inhomogeneities (Fig. A21.1.2 and Fig. A21.1.3). The auto-
Table A21.1.7 Primary Clinical Imaging Parameters for T1-Weighted Gradient
Echo (Post-Contrast) Scan (Sequence 5)
Patient position Prone
Scan type T1-weighted 2-D gradient echo
Imaging plane (orientation) Transverse
Central slice or volume center Middle of the breast
Echo time (TE) 5 msec
Repeat time (TR) 100 msec
Flip angle (FA) 80°
Fields of view (FOVx, FOVy) 315 mm, 350 mm
Resolution (∆x, ∆y) 1.23 mm, 1.37 mm
Number of data points collected (Nx, Ny) 256, 256
Slice thickness (∆z) 3–5 mm
Number of slices 24
Slice gap 0.1–1.0 mm
Number of acquisitions (Nacq) 1
Number of repetitions 7
Scan time 1 min, 0 sec (after 7 repetitions
the scan time adds to 7 min)
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Figure A21.1.2 Four images of the same slice before
injection of contrast medium (upper left) and 1 min (upper
right), 2 min (lower left) and 7 min (lower right) after
injection of contrast medium. Strong initial signal in-
creases in a focal lesion (ductal invasive cancer) as well
as segmental, dotted increases in the left segmental area
oriented towards the nipple (neighbored DCIS). Signal
decreases (washout) in the focal lesion in the late scan.
These signal changes can be better detected in the
corresponding subtractions in Figure A21.1.3.
Figure A21.1.3 Here the image subtractions (post-mi-
nus pre-contrast scan) are seen after 1 min (upper left),
2 min (upper right), 3 min (lower left), and 7 min (lower
right) post-contrast injection. The focal lesion including
the washout effect as well as the corresponding segmen-
tal enhancement in the DCIS are documented.
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matic data evaluation enables a real time navigation through all slices in four
dimensions (three spatial dimensions and one time dimension).
25. However, pitfalls concerning automatic data evaluation should not be overlooked (see
Critical Parameters and Troubleshooting). Some examples are an inadequate or
wrong injection technique; an inappropriate receiver/transmitter adjustment; a mis-
interpretation of inflow phenomena; hormone effects, and vessels as lesions.
Sequence 6: coronal T1-weighted gradient echo (post-contrast scan)
The final examination is a repetition of the T1-weighted gradient echo sequence in the
coronal orientation.
26. Run sequence 6 according to Table A21.1.4.
27. After the last post-contrast scan at checkpoint III (see Fig. A21.1.1), the contrast
uptake is tested according to enhancement in breast parenchyma, vessels, muscles,
etc.
The constancy of tuning parameters during the complete time of the dynamic scan has to
be checked by a constant time-intensity curve in the fatty tissue, because that does not
enhance. If the fat signal is inhomogeneous and/or varying over time, the signal-intensity
versus time curve is not helpful or will be misleading (see Critical Parameters and
Troubleshooting).
ALTERNATE
PROTOCOL 1
MR IMAGING BY CONTRAST-ENHANCED DYNAMIC 3-D TECHNIQUE
In the past years, different dynamic techniques have been evaluated, including multi-slice
2-D (see Basic Protocol) or 3-D techniques. 3-D scans allow a better spatial resolution
with thinner slices. However, the homogeneity of 3-D sequences on some machines has
been limited, so that inhomogeneity artifacts deteriorated the kinetic data evaluation.
Today both multi-slice 2-D and 3-D sequences can be applied with equal results in most
machines, and therefore this alternate protocol is given in detail here.
Table A21.1.8 Primary Clinical Imaging Parameters for Scout Scan (Sequence 7)
Patient position Prone
Scan type 3-D gradient echo
Imaging plane (orientation) Transverse or coronal (but not
sagittal)
Central slice or volume center Centered at the nipple level
Echo time (TE) As short as possible (but in a
“in-phase” echo time, i.e.,
multiple of 4.8 msec)
Repeat time (TR) As short as possible (e.g., 10 msec)
Flip angle (FA) 10° to 15°
Fields of view (FOVx, FOVy) 350 mm, 350 mm
Resolution (∆x, ∆y) 1.37 mm, 1.37 mm
Number of data points collected (Nx, Ny) 256, 256
Slice thickness (∆z) 1–2 mm (depending on breast size)
Number of slices 48
Slice gap No gap
Number of acquisitions (Nacq) 1
Scan time <90 sec (depending on TR)
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Set up equipment and patient
1. Use the same equipment and perform patient set-up as for the previous method (see
Basic Protocol, steps 1 to 13). This is also valid for the establishment of an intervenous
line as well as the information and informed consent obtained from the patient.
Sequence 7: Scout scan
2. Run a rapid 3-D pilot scan to demonstrate the position of the breast in the coil (Table
A21.1.8).
One can also run sequence 1 (Table A21.1.3) instead.
Sequence 8: 3-D short TR gradient echo scans
3. Run a 3-D short TR gradient echo sequence according to Table A21.1.9.
4. Repeat steps 20 and 21 of the Basic Protocol (to inject the contrast agent).
5. After a 20 sec wait time, run the 3-D gradient echo sequence 5 times according to
Table A21.1.9 to get 6 data points for a signal-intensity time curve.
This is not the same as setting the number of acquisitions to be 5.
ALTERNATE
PROTOCOL 2
FAT-SATURATED 3-D SCAN: HIGH SPATIAL RESOLUTION
In the United States fat saturation techniques have been evaluated which focus especially
on the high spatial resolution used to describe morphological features of lesions. These
techniques are also mentioned in this unit.
Set up equipment and patient
1. Use the same equipment and perform the same patient set up as in the Basic Protocol
(steps 1 to 14).
Sequence 9: 3-D short TR gradient echo scans: fat suppression
2. Run a 3-D short TR gradient echo sequence according to Table A21.1.10.
3. Repeat steps 20 and 21 of the Basic Protocol (to inject the contrast agent).
Table A21.1.9 Primary Clinical Imaging Parameters for Dynamic 3D MR
Mammography at 1.5 T (Sequence 8)
Patient position Prone
Scan type 3-D short TR gradient echo
Imaging plane (orientation) Transverse
Central slice or volume center Middle of the breast
Echo time (TE) 4 msec
Repeat time (TR) 8.1 msec
Flip angle (FA) 20°
Fields of view (FOVx, FOVy) 320 mm, 240 mm
Resolution (∆x, ∆y) 1.25 mm, 1.25 mm
Number of data points collected (Nx, Ny) 256, 192
Slice thickness (∆z) 1–2 mm
Number of slices 48
Slice gap 0
Number of acquisitions (Nacq) 1
Fat suppression Temporal subtraction
Scan time 75 sec
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4. After a 20-sec wait time, run the 3-D gradient echo sequence twice according to Table
A21.1.10.
This is not the same as setting the number of acquisitions to be 2.
ALTERNATE
PROTOCOL 3
FAT-SATURATED 3-D SCAN: RODEO (ROTATING DELIVERY OF
EXCITATION OFF-RESONANCE)
As mentioned in Alternate Protocol 2, this is another alternate protocol to describe
morphological features of lesions.
Set up equipment and patient
1. Use the same equipment and perform the same patient setup as in the Basic Protocol
(steps 1 to 14).
Table A21.1.10 Primary Clinical Imaging Parameters for Focusing High Spatial
Resolution at the Cost of High Temporal Resolution (Sequence 9)
Patient position Prone
Scan type 3-D short TR gradient echo
Imaging plane (orientation) Sagittal (dual volume) with lateral
compression
Central slice or volume center Middle of the breast
Echo time (TE) 2.2 msec
Repeat time (TR) 22 msec
Flip angle (FA) 30°
Fields of view (FOVx, FOVy) 160 mm, 160 mm
Resolution (∆x, ∆y) 0.31 mm, 0.625 mm
Number of data points collected (Nx, Ny) 512, 256
Slice thickness (∆z) 1.875 mm
Number of slices 32
Slice gap 0
Number of acquisitions (Nacq) 1
Fat suppression Yes
Scan time 180 sec
Table A21.1.11 Primary Clinical Imaging Parameters for RODEO (see Harms
et al., 1993; Sequence 10)
Patient position Prone
Scan type 3-D short TR gradient echo
Imaging plane (orientation) Sagittal
Central slice or volume center Middle of the breast
Echo time (TE) 5 msec
Repeat time (TR) 20 msec
Flip angle (FA) 45°
Fields of view (FOVx, FOVy) 120 mm, 120 mm
Resolution (∆x, ∆y) 0.47 mm, 0.94 mm
Number of data points collected (Nx, Ny) 256, 128
Slice thickness (∆z) 1.2 mm
Number of slices 128
Slice gap 0
Number of acquisitions (Nacq) 1
Fat suppression Yes
Scan time 320 sec
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Sequence 10: 3-D short TR gradient echo scans: fat suppression
2. Run a 3-D short TR gradient echo sequence according to Table A21.1.11.
3. Repeat steps 20 and 21 of the Basic Protocol (to inject the contrast agent).
4. After a 20-sec wait time, run the 3-D gradient echo sequence according to Table
A21.1.11.
COMMENTARY
Background Information
The development of MR Mammography
has included several phases up to now. At first
MR tomography in general had to be devel-
oped, then special breast coils (single breast
coils, followed by double breast coils and later
combined imaging/interventional coils) had to
be built and optimized. Contrast media were
used at first in spin-echo sequences and later in
sophisticated so-called “dynamic” techniques
using gradient echo sequences for a better dif-
ferential diagnosis. The main topics today are
technological optimization, evaluation of diag-
nostic criteria, and development of interven-
tional procedures.
Already in 1971 different relaxation times
in tumor tissue as compared with normal tissue
were measured using in vitro experiments
(Damadian, 1971). However, MR imaging of
the human body was possible only after the
application of local gradient fields (Lauterbur,
1973). The first tissue samples of the breast
were published by Mansfield (1979). These
tissue samples were taken ∼90 min after opera-
tion. The first in vivo images of whole-body
MR machines from 128 breasts of 65 patients
including 7 cancers were taken in 1982 (Ross
et al., 1982). In these reports a whole-body
scanner in a field strength of 0.045 T was used
and each patient was imaged in a supine posi-
tion, providing 2 proton density–weighted im-
ages and 6 T1 relaxation time measurements. In
1983, El-Yousef published results of 2 patients
using an experimental surface coil in a field
strength of 0.03 T and reported a reduced signal
intensity of both cancers. In a following publi-
cation, El-Yousef (1984) reported images of 10
volunteers and 45 patients describing a reduced
signal intensity of breast lesions in spin echo
and inversion-recovery sequences.
Starting in 1983, special breast coils were
developed which were used only for breast
imaging and later sold commercially. Until
1986 only single breast coils were available
(Fritschy et al., 1984; Kaiser, 1985; Stelling et
al., 1985). After first disappointing trials in a
supine position, the examinations were per-
formed in a prone position to minimize move-
ment and artifacts caused by breathing. How-
ever, at that time the available spin-echo and
inversion-recovery sequences did not allow a
definite detection and differentiation of small
lesions in all cases, yet the advantage of imag-
ing in thin slices in any orientation in a variable
soft tissue contrast without X-rays was already
clear (Heywang et al., 1985; Kaiser and Zeitler,
1986a,b). Further progress was the develop-
ment and introduction of the MR contrast me-
dium Gadolinium-DTPA (Weinmann et al.,
1984), because experiments were possible in
analogy to computer tomographic results using
ionized X-ray contrast medium and radioactive
iodine uptake from the mid 1970s (Eskin et al.,
1974; Chang et al., 1978). The first group,
which got and used contrast medium, was Hey-
wang et al. (1986). Initially spin-echo se-
quences in relatively long examination times
and high contrast dosages were applied and
reported; however, the uptake of contrast me-
dium of cancers, normal tissue, and prolifera-
tive changes could not be differentiated suffi-
ciently. After the introduction of fast gradient
echo sequences (Haase et al., 1986), the first
dynamic examinations were established that
used repetitive measurements of the same slices
before and in short- time intervals after contrast
medium injection (Kaiser and Oppelt, 1987;
Kaiser and Zeitler, 1989). However how to
better differentiate between benign and malig-
nant lesions was the subject of scientific dis-
cussion for a long time (see subsection in Lit-
erature Cited listing References on Differenti-
ating Benign and Malignant Breast Lesions).
The following development of a double breast
coil (Kaiser and Kess, 1989) allowed routine
measurements of both breasts of a patient in a
single examination with a good signal-to-noise
ratio.
After these initial steps, a period of evalu-
ation of dynamic techniques using different
measurement sequences and dosages followed,
mainly in Europe. Since 1991 American groups
reported contrast-enhanced MR Mammogra-
phy, too, using mainly fat saturation sequences
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(Harms et al., 1993; Orel et al., 1995) in single
breast coils. The results of the enormous variety
of measurement techniques were confusing and
resulted in a wide variation of opinion about
the usefulness of MR Mammography (Kaiser,
1996).
By using MR Mammography, doctors could
detect small lesions on the size of a few milli-
meters. These lesions were often not seen by
X-ray or ultrasound. Therefore, the need for the
development of interventional MR procedures
increased, at first for positioning of markers,
later for biopsy and therapeutic removal (Huss-
man et al., 1993; de Souza et al., 1995; Silver-
man et al., 1995; Doler et al., 1996; Mahfouz
et al., 1996; Sittek et al., 1996; Kuhl et al., 1997;
Wurdinger et al., 1997; Thiele et al., 1998). Up
to now these techniques required additional
MR imaging on another day, i.e., a second
measurement in a repetitive use of the MR
device and contrast medium injection. At pre-
sent, single breast biopsy coils in so-called
“closed” as well as in “open” MR machines are
tested. A bilateral coil for combined imaging
and simultaneous intervention has been clini-
cally tested since 1997 (Wurdinger et al., 1997).
Today modern high-field MR machines
(above 1.0 T) do not allow direct access to the
breasts during data acquisition. The patient has
to be in the isocenter of the main magnetic field
during imaging and must be moved outside the
machine for the following intervention. The
position of a wire marking, a core biopsy, or a
laser fiber has to be checked after the position-
ing of the interventional device with further
imaging in the MR machine, therefore increas-
ing measurement time, artifacts and pitfalls. An
MR compatible robotic system for simultane-
ous imaging and immediate biopsy/interven-
tion at high field strength is in clinical testing
(Kaiser et al., 2000).
Critical Parameters and
Troubleshooting
MR Mammography has to be performed in
pre- and post-contrast scans to detect the tumor-
specific vessel structure which is called tumo-
rangiogenesis. Up to now a non-contrast scan
alone is insufficient in detecting very small
lesions. In addition to morphological evalu-
ations, the time intensity curve is very impor-
tant in making the diagnosis. The signal inten-
sity in the first post-contrast images is abso-
lutely crucial for a correct interpretation of the
data. This first contrast signal intensity image
depends critically on exact measurement pa-
rameters. Injection time, injection site, sodium
chloride bolus, length of plastic tube, arm po-
sition, and tuning parameters are major factors
of this critical image signal intensity.
According to our experience, an increase of
>90% of signal intensity in the first 90 sec after
the start of contrast medium injection (“90-90
rule”) is a threshold for a malignant enhance-
ment using 2-D dynamic imaging at 1.5 T (Fig.
A21.1.4 and Fig. A21.1.5). To reach this critical
threshold, the measurement using a region of
interest (ROI) procedure has to be performed
carefully. Only the “vital” tumor areas (Fig.
A21.1.5 and Fig. A.21.1.6) show a critical in-
itial enhancement followed by a plateau phe-
nomenon or a washout effect. An inclusion of
necrotic areas of the tumor or surrounding nor-
mal glandular or fatty tissue will deteriorate and
kinetic description
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Figure A21.1.4 Signal intensity versus time curve showing relative (percentage) changes of
signal after injection of contrast agent: the early (“initial”) and later (“delayed”) phases are described
separately.
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falsify the effect of kinetic data evaluation. It is
necessary to look for the fastest enhancing
portion of the lesion.
It is also important not to include just any
enhancing spot and describe it as malignant.
Vessels are cut in different orientations in the
slice and are therefore displayed in a round,
oval or comet shaped manner. The observance
of inflow phenomena, the delineation of vessels
in other slices or other orientations or, if you
have still any doubts, an additional MR angiog-
raphy sequence (see Chapter A1 for MRA se-
quence) all help clarify whether the tiny en-
hancing area is a vessel or not.
Fat saturation techniques are in a relatively
widespread use in the United States. They allow
a pretty high spatial resolution, but have a
limited value in the kinetic data evaluation.
Since a pre-pulse in a low bandwidth is neces-
sary, the adjustment parameters in pre- and
post-contrast scans are not identical. Present fat
saturation techniques usually have a relatively
high signal inhomogeneity, so that a quantita-
tive evaluation is difficult and subtractions are
difficult, nevertheless often necessary. The
measurement time in most cases is longer than
in non fat saturation techniques and the “diag-
nostic window” for the detection of differences
between benign and malignant enhancement
criteria is restricted.
Fat suppression methods may either be by
temporal subtraction (which is ideal for fat
Figure A21.1.5 Nine images of the same slice before (upper left) and every minute after
injection of contrast medium: a malignant lesion shows a striking initial signal increase
especially in the tumor periphery and a constancy of signal intensity during the following
dynamic examination. Note the slower signal change of the normal breast parenchyma.
internal filling
dynamic MRM
centripetal centrifugal
Figure A21.1.6 Different types of enhancement after injection of contrast medium: centrifugal
(from inside to outside) and centripetal (from outside to inside). 
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suppression, since only enhancing structures
are delineated as high signal intensity lesions),
or by pre-pulses with the above-mentioned
limitations present.
The injection of contrast medium is made in
a bolus (3 ml/sec) either manually or by an
automatic injector followed by a post-contrast
bolus of physiological sodium chloride of 20
ml (cubital vein) or 30 ml (lower arm/hand). It
is preferable not to move or talk to the patient
during injection, but rather to explain the pro-
cedure before positioning the patient in the
machine. According to our experience, the dose
of contrast medium should not be higher than
0.1 mmol/kg. A higher dose shortens the al-
ready short “diagnostic window”, i.e., the time
difference of only 1 to 2 min where the contrast
uptake between malignant and benign lesions
is sufficiently different in order to enable a
differential diagnosis.
The data evaluation begins by looking at
fatty tissue on both breasts and to control if the
signal intensity of fatty tissue is constant eve-
rywhere in the breast. If this signal intensity of
fatty tissue as an “internal standard” varies,
consider that it might be due to a changing
receiver adjustment or field inhomogeneity ef-
fects or artifacts. In these cases a quantitative
evaluation is difficult or impossible, since the
technical problems overlap any morphological
information.
Dynamic MRM should be performed using
transverse scans (sequence 5), because in this
orientation the identification of vessels, nip-
ples, posterior borders of implants, fatty layer
between parenchyma and muscle, signal homo-
geneity of the coil and signal correlation with
the aorta is much easier. However, if the lateral
border of the parenchyma towards the axillary
region and/or lymph nodes is especially impor-
tant, a dynamic MRM in coronal scans is ad-
vantageous. A sagittal orientation should be
avoided because of doubled measurement time
and the lack of correlation with the other breast.
Furthermore, it is difficult to detect inflow phe-
nomena and hormone effects, etc., in this ori-
entation
If only the axillary region is important, the
rotation of phase encoding direction towards a
dorsoventral orientation is recommended to
keep the lateral axillary region free of phase
encoding artifacts.
It is of crucial importance to use echo times
where fat and water protons are in “in-phase”
conditions, because only in these echo times
will Gd have a signal-increasing effect on the
water protons in the voxel. Especially tiny re-
ticular structures like DCIS or lobular cancers
can be examined only in this “in-phase” image.
“In-phase” situations for 1.5 T are even multi-
ple numbers of 2.4 msec, i.e., 4.8 msec, 9.6
msec, etc. Odd multiple numbers of 2.4 msec,
for example, 7.2 msec, are “forbidden” because
of the “opposed effect” of water and fat protons.
This effect is field strength dependent and
should be adjusted according to the field
strength used.
During the dynamic examination it is essen-
tial not to change tuning parameters between
scans in order to guarantee identical pulses in
pre- and post-contrast scans. Only under these
conditions is a correct signal intensity versus
time evaluation possible.
The pre-contrast signal intensity of paren-
chyma should be in a typical range for this
sequence. If it is too low, look for an inappro-
priate receiver adjustment or inappropriate coil
as the problem and try to change the receiver
adjustment. If this pre-contrast signal intensity
is too high, it could also suggest an inappropri-
ate receiver adjustment or some other medi-
cal/biological reason for the problem, such as
bleeding after puncture/biopsy, hormone ef-
fect, pregnancy, previous operation and/or ra-
diation.
Anticipated Results
Morphological and kinetic information
Diagnosis of breast lesions in MR Mam-
mography is always made by a combined mor-
phological and kinetic analysis. It is the main
feature of MRM that tumortypic “tumorangio-
genesis” can be detected by signal intensity
versus time curves. Various curves are listed in
Figure A21.1.4. A typical malignant lesion
shows the striking initial increase (wash-in phe-
nomenon) within the first 1 to 2 min after the
injection of contrast medium followed by either
a constant signal (plateau phenomenon) or—
more specifically—a decrease in signal inten-
sity (washout effect). The sudden increase and
the following constancy or washout effect make
the so-called “cancer-corner” of the signal-time
curve. Benign lesions normally show a slower
initial increase which is continuouly rising over
the complete dynamic examination. Morpho-
logical analysis describes the type of enhance-
ment as shown schematically in Figure
A21.1.6. The distribution of a lesion is de-
scribed as either regional or patchy or diffuse
or symmetric, and the morphology of the lesion
itself is described as a focal mass with sharp or
non-sharp margins, linear, linear-branched, or
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segmental aspects (Harms, 1999). The initial
and late enhancement is described as being
homogeneous, heterogeneous, rim enhance-
ment, bright or dark septations after contrast
medium injection and centripetal or centrifugal
filling effect over time. A centrifugal filling
(from inside to outside) directs mainly towards
a benign lesion, a centripetal filling (from out-
side to inside) towards a malignant lesion (Fig.
A21.1.6). An overview of the morphological
analysis according to shape, margins and en-
hancement is listed in Table A21.1.12.
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